September 29, 2020 6:38pm

Another I told you so …

Pre-open indication results: 7 HITs and 0 MISS

An “intelligence newspaper” for smart investing in the RegMed, gene and cell therapy sector.  I say today what others won't, so you can do what others can't.

Subscription is coming, my gift to you, I've kept RMi subscription FREE during these COVID-19 and volatile times!

The Dow closed DOWN -131.40 points (- 0.48%), the S&P closed DOWN – 16.13 points (- 0.48%) while the Nasdaq closed DOWN -32.28 points (-0.29 %)

 

Henry’omics:

Indexes fell on Tuesday while … amid renewed concern over the coronavirus outbreak in New York City.

September has been a tough month for traders and investors as major averages headed for their first monthly decline since March. Month to date, the S&P 500 has dropped 4.6% and the Dow has lost 3.5% while the Nasdaq is down 5.6%.

Since tonight’s election debate been a very talkative subject today; the first debate of this cycle just might be consequential for the markets than most debates, with a clear victory by one candidate possibly creating significant market moves.

From today’s Data Docket: The Conference Board said consumer confidence jumped much more than expected, hitting a print of 101.8 for September. Economists expected consumer confidence to rise to 90.1 from 86.3 in August.

 

This morning, I stated in this a.m.’s newsletter – RegMed Investors’ (RMi) pre-open: anticipation versus expectation and realization … https://www.regmedinvestors.com/articles/11566

 

Pre-open indications: 7 HITs < Biostage (BSTG -$0.19), Sell into Strength -Athersys (ATHX -$0.05), BioLife Solutions (BCLI +$1.63) Fate Therapeutics (FATE -$1.10), Cellectis SA (CLLS +$0.06), CRISPR Therapeutics (CRSP +$1.30), Mesoblast (MESO -$0.25)> and 0 MISS

 

RegMed/Cell and Gene therapy 35 covered equities’ Advance/Decline (A/D) lines: progressions and regressions …

  • Tuesday opened positive at 2013 and 2 flats, slipped neutral at the mid-day at 16/13 and 3 flats, closing negative at 16/18 and 1 flat;
  • Monday opened positive at 23/8 and 4 flats, slipped negative at the mid-day at 15/18 and 2 flats, closing neutral at 16/16 and 3 flats;
  • Friday opened positive at 29/5 and 1 flat, stayed positive at the mid-day at 27/7 and 1 flat, closing positive at 32/2 and 1 flat;

 

Key metrics:

  • Sector volume was extremely LOW with 0 of the 16-upside having higher than the 3-month average volume with the 2 of 18-downside having higher than the 3-month average volume;
  • Tuesday’s percentage (%) of the 16-upside was +0.32% (CLLS) to +6.64% (PSTI) while the 18-downside ranges from -0.20% (SGMO) to -10.92% (BSTG); 

 

Hammered in today’s market:

  • ReNeuron (RENE.L), Fate Therapeutics (FATE), bluebird bio (BLUE), Ionis Pharmaceuticals (IONS), uniQure NV (QURE) to name 5 of the 18 declining of the 35 covered

Jumping with share pricing momentum:

  • Alnylam Pharmaceuticals (ALNY), Ultragenyx (RARE), BioLife Solutions (BLFS), CRISPR Therapeutics (CRSP), Pluristem (PSTI) to name 5 of the 16 inclining of the 35 covered

 

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Tuesday, the IBB closed up +0.10% and XBI closed up +0.68%
  • Monday, the IBB closed up +0.76% and XBI closed up +0.12%
  • Friday, the IBB closed up +2.13% and XBI closed up +2.54%

 

Tuesday’s (10 of 16) incliners:

  • Alnylam Pharmaceuticals (ALNY +$5.20 after Monday’s +$1.50 and Friday’s +$4.97),
  • Ultragenyx (RARE +$2.60 after Monday’s +$0.65 and Friday’s +$2.06);
  • BioLife Solutions (BLFS +$1.63 after Monday’s +$0.78);
  • CRISPR Therapeutics (CRSP +$1.30 after Monday’s -$0.40 and Friday’s +$0.78);
  • Pluristem (PSTI +$0.63);
  • Regenxbio (RGNX +$0.55 after Monday’s -$0.49 and Friday’s +$0.84);
  • Intellia Therapeutics (NTLA +$0.39);
  • Bellicum Pharmaceuticals (BLCM +$0.34);
  • Global Blood Therapeutics (GBT +$0.31 after Monday’s-$0.55 and Friday’s +$0.83);
  • Brainstorm Cell Therapeutics (BCLI +$0.24 after Monday’s +$1.00 and Friday’s +$0.76),

Tuesday’s (10 of 18) decliners:

  • ReNeuron (RENE.L -$2.50 after Monday’s +$0.50 and Friday’s -$4.00);
  • Fate Therapeutics (FATE -$1.10 after Monday’s +$2.70 and Friday’s +$1.81),
  • bluebird bio (BLUE -$0.90 after Monday’s -$1.14 and Friday’s +$1.37);
  • Ionis Pharmaceuticals (IONS -$0.55 after Monday’s +$0.33);
  • uniQure NV (QURE -$0.43 after Monday’s -$0.94);
  • AxoGen (AXGN -$0.28);
  • MiMedx (OTC Pink sheets: MDXG -$0.26 after Monday’s +$0.22);
  • Mesoblast (MESO -$0.25 after Monday’s +$1.90),
  • Sage Therapeutics (SAGE -$0.22 after Monday’s -$0.93 and Friday’s +$1.92);
  • Biostage (BSTG -$0.19);

Closing flat: 1 – Stemline Therapeutics (STML) – acquired)

 

Percentage (%) movement/range statistics: 360 degrees comparisons

  • Tuesday’s percentage (%) of the 16-upside was +0.32% (CLLS) to +6.64% (PSTI) while the 18-downside ranges from -0.20% (SGMO) to -10.92% (BSTG); 
  • Monday’s percentage (%) of the 16-upside was +0.52% (RARE) to +10.83 (MESO) while the 16-downside ranges from -0.28% (NTLA) to -4.35% (ADVM); 
  • Friday’s percentage (%) of the 32-upside were +0.12% (IONS) to +12.58% (BSTG) while the 2-downside ranges from -0.52% (VYGR) to -4.40% (RENE.L); 

 

Sentiment and a few daily indicators:

We’re not out of the woods yet in terms of the coronavirus … infection rates are expanding effecting sentiment.

The global death toll of the coronavirus has now crossed 1 million people, nine months after the virus was first discovered in Wuhan, China.

Infection cases:

  • Tuesday 7.16 cases
  • Monday 7.12 M cases
  • Friday 6.98 M cases

Tuesday’s death rate totaled 205,547 after Monday’s 204,881, Friday’s 202,827, Thursday’s 201,920, Wednesday’s 200,818 and last Tuesday’s 200,005 <Johns Hopkins University>

 

Stats:

Upside volume: 

  • Tuesday: 0 out of the 16-upside had higher than the 3-month average volume;
  • Monday: 2 out of the 16-upside had higher than the 3-month average volume;
  • Friday: 4 out of the 32-upside had higher than the 3-month average volume;

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Tuesday was up +0.08 points or +0.31% at 26.27
  • Monday was down -0.19 points or -0.72% at 26.19
  • Friday was down -2.13 points or -7.47% at 26.38

Downside volume:

  • Tuesday: 2 out of the 18-downside had higher than the 3-month average volume;
  • Monday: 3 out of the 16-downside had higher than the 3-month average volume;
  • Friday: 0 out of the 2-downside had higher than the 3-month average volume;

 

September, the third month of Q3 …

Tuesday closed negative with 16 advancers, 18 decliners and 1 flat

Monday (9/28) closed neutral with 16 advancer, 16 decliners and 3 flats

Friday closed positive with 32 advancers, 2 decliners and 1 flat

Thursday closed negative with 4 advancers, 29 decliners and 2 flats

Wednesday closed negative with 7 advancers, 27 decliners and 1 flat

Tuesday closed positive with 20 advancers, 13 decliners and 1 flat

Monday (9/21) closed negative with 1 advancer, 33 decliners and 1 flat

Friday closed positive with 29 advancers, 5 decliners and 1 flat

Thursday closed negative with 13 advancers, 20 decliners and 2 flats

Wednesday closed positive with 23 advancers, 10 decliners and 2 flats

Tuesday closed positive with 22 advancers, 12 decliners and 1 flat

Monday (9/14) closed positive with 31 advancers, 3 decliners and 1 flat

Friday closed negative with 16 advancers, 17 decliners and 2 flats

Thursday closed negative with 12 advancers, 20 decliners and 3 flats

Wednesday closed positive with 27 advancers, 5 decliners and 3 flats

Tuesday (9/10) closed negative with 14 advancers, 19 decliners and 2 flats

Monday was a holiday 

Friday closed negative with 5 advancers, 28 decliners and 2 flats

Thursday closed negative with 2 advancers, 32 decliners and 1 flat

Wednesday closed negative with 18 advancers, 25 decliners and 2 flats

Tuesday (9/1) closed negative with 4 advancers, 29 decliners and 2 flats

 

The Bottom Line: Share pricing is on a trampoline in the RegMed, cell and gene therapy sector.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.